Skip to main content
Journal cover image

TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.

Publication ,  Journal Article
Barbagelata, NA; Granger, CB; Oqueli, E; Suárez, LD; Borruel, M; Topol, EJ; Califf, RM
Published in: Am Heart J
March 1997

Early and sustained flow of grade 3 according to Thrombolysis in Myocardial infarction (TIMI) criteria and reocclusion rates are the key measures that define the physiologic efficacy of thrombolytic agents in the treatment of acute myocardial infarction. We performed a systematic overview of angiographic studies after intravenous thrombolysis with accelerated and standard-dose tissue-plasminogen activator (TPA), anisoylated plasminogen streptokinase activator complex (APSAC), and streptokinase. There were 5475 angiographic observations from 15 studies for TIMI flow analysis and 3147 angiographic observations from 27 studies for reocclusion. At 60 and 90 minutes, the rates of TIMI grade 3 flow were 57.1% and 63.2%, respectively, with accelerated TPA, 39.5% and 50.2% with standard-dose TPA, 40.2% and 50.1% with APSAC, and 31.5% at 90 minutes with streptokinase. Overall reocclusion with standard-dose TPA was 11.8% versus 6.0% for accelerated TPA, 4.2% for streptokinase, and 3.0% for APSAC. Although the incidence of TIMI grade 3 flow increased over time with all thrombolytic regimens, decreased patency was observed at 180 minutes with accelerated TPA. Still, accelerated TPA is the most effective agent to establish early (90-minute) TIMI grade 3 flow.

Duke Scholars

Published In

Am Heart J

DOI

ISSN

0002-8703

Publication Date

March 1997

Volume

133

Issue

3

Start / End Page

273 / 282

Location

United States

Related Subject Headings

  • Vascular Patency
  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Streptokinase
  • Regional Blood Flow
  • Recurrence
  • Plasminogen Activators
  • Myocardial Infarction
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Barbagelata, N. A., Granger, C. B., Oqueli, E., Suárez, L. D., Borruel, M., Topol, E. J., & Califf, R. M. (1997). TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J, 133(3), 273–282. https://doi.org/10.1016/s0002-8703(97)70220-5
Barbagelata, N. A., C. B. Granger, E. Oqueli, L. D. Suárez, M. Borruel, E. J. Topol, and R. M. Califf. “TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.Am Heart J 133, no. 3 (March 1997): 273–82. https://doi.org/10.1016/s0002-8703(97)70220-5.
Barbagelata NA, Granger CB, Oqueli E, Suárez LD, Borruel M, Topol EJ, et al. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J. 1997 Mar;133(3):273–82.
Barbagelata, N. A., et al. “TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis.Am Heart J, vol. 133, no. 3, Mar. 1997, pp. 273–82. Pubmed, doi:10.1016/s0002-8703(97)70220-5.
Barbagelata NA, Granger CB, Oqueli E, Suárez LD, Borruel M, Topol EJ, Califf RM. TIMI grade 3 flow and reocclusion after intravenous thrombolytic therapy: a pooled analysis. Am Heart J. 1997 Mar;133(3):273–282.
Journal cover image

Published In

Am Heart J

DOI

ISSN

0002-8703

Publication Date

March 1997

Volume

133

Issue

3

Start / End Page

273 / 282

Location

United States

Related Subject Headings

  • Vascular Patency
  • Treatment Outcome
  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Streptokinase
  • Regional Blood Flow
  • Recurrence
  • Plasminogen Activators
  • Myocardial Infarction
  • Humans